Kona Medical, Inc. is a privately held company developing an innovative and non-invasive therapy for treatment of hypertension (high blood pressure). Kona was founded in 2009, is headquartered near Seattle in Bellevue, Washington, and is actively supported by leading medical technology investors. Kona is developing an ultrasound-based approach to address severe high blood pressure (hypertension) through ablation of the renal nerves. Renal nerves are located proximal to the renal arteries, which provide blood flow to the kidneys. Renal nerves are part of the sympathetic nervous system and play a significant role in determining blood pressure. Recent clinical data have shown that ablation of renal nerves can result in profound and lasting reduction in hypertension in patients whose blood pressure is not adequately controlled by medication.
Industry analysts have forecast that the future market for devices to effect renal denervation may reach several billion dollars worldwide. Kona’s proprietary technology, which utilizes externally delivered ultrasound energy to ablate the renal nerves, can enable non-invasive treatment for drug-resistant hypertension and has significant potential advantages over alternative methods.
Note: Kona Medical’s technology is investigational and is not yet approved by the US Food and Drug Administration.